Lupin shares rebound on USFDA nod for anti-hypertensive drug

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

Choose Stock Exchange: BSE LIVE NSE LIVE

26 Aug, 2025 12:21

Volume

Todays L/H

More

×

Moneycontrol Bureau

Lupin shares recovered 2.5 percent from day's low to trade more than half a percent higher after getting approval from the US health regulator for antihypertensive drug.

The pharma major has received tentative approval for its Olmesartan Medoximil tablets, 5 mg, 20 mg and 40 mg from the United States Food and Drug Administration (FDA) to market in the US, the world's largest drug market.

These tablets are the AB rated generic equivalents of Daiichi Sankyo Inc's Benicar tablets, 5 mg, 20 mg and 40 mg.

Olmesartan Medoximil tablets are indicated for the treatment of hypertension, along or with other antihypertensive agents to lower blood pressure.

Benicar tablets had US sales of USD 1.06 billion, according to IMS MAT data of September 2016.

At 11:05 hours IST, the stock was quoting at Rs 1,455.00, up Rs 9.65, or 0.67 percent on the BSE.Posted by Sunil Shankar Matkar